Buy IDRA-21 powder (22503-72-6) hplc≥98% – Nootropics Wisepowder
Chemical name 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide
Synonyms IDRA-21; IDRA 21; IDRA21.
Molecular Formula C8H9ClN2O2S
Molecular Weight 232.682
Melting Point Unknow
InChI Key VZRNTCHTJRLTMU-UHFFFAOYSA-N
Appearance White to off-white solid powder
Half Life 24/36 hours
Solubility soluble in DMSO (100mM)
Storage Condition Store at RT
Application An analog of cyclothiazide that Inhibits AMPA receptor desensitization
Testing Document Available
03 IDRA-21 (22503-72-6) General Description
IDRA-21 powder is classified as an ampakine. It is able to improve focus and attention as well as promote learning and memory. Ampakines are growing in popularity largely because they provide the cognitive benefits of stimulants without the undesirable side effects.
In a 1995 study done on rats, IDRA-21 reduced cognitive deficits induced by alprazolam (Xanax). That same year, another study showed cognitive impairment induced by scopolamine was reversed in monkeys by IDRA-21. No human studies have been done.
04 IDRA-21 (22503-72-6) History
IDRA-21 powder is a positive allosteric modulator of the AMPA receptor and a benzothiadiazine derivative. It is a chiral molecule, with (+)-IDRA-21 being the active form.
IDRA-21 was bio-active in animal studies, significantly improving learning and memory. It is around 10–30 times more potent than aniracetam in reversing cognitive deficits induced by alprazolam or scopolamine, and produces sustained effects lasting for up to 48 hours after a single dose.The mechanism for this action is thought to be through promoting the induction of long-term potentiation between synapses in the brain.
In comparison to the ampakines or benzoylpiperidine-derived AMPA receptor potentiators, IDRA-21 was more potent than CX-516, but less potent than CX-546. Newer benzothiadiazide derivatives with greatly increased potency compared to IDRA-21 have been developed, but these have not been researched to the same extent, with the benzoylpiperidine and benzoylpyrrolidine CX-series of compounds being favoured for clinical development, most likely due to more favourable toxicity profiles at high doses.